BiondVax Pharmaceuticals Ltd. Sponsored ADR Stock

$2.57

5.17% today

Nasdaq, Apr 04, 09:17 pm CET

ISIN

US09073Q1058

Symbol

SCNI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

BiondVax Pharmaceuticals Ltd. Sponsored ADR Stock price

$2.71

-717.29 99.62% 5Y

Nasdaq, Closing price Thu, Apr 03 2025

-0.14 4.91%

ISIN

US09073Q1058

Symbol

SCNI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$2.31m
Enterprise Value	$8.00m
P/E (TTM) P/E ratio	8.88
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	17.78
P/S ratio (TTM) P/S ratio	5.13
P/B ratio (TTM) P/B ratio	0.53
Revenue (TTM) Revenue	$450.00k
EBIT (operating result TTM) EBIT	$-8.25m
Free Cash Flow (TTM) Free Cash Flow	$-6.83m
Cash position	$1.17m
EPS (TTM) EPS	$0.31
Short interest	1.30%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

BiondVax Pharmaceuticals Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast BiondVax Pharmaceuticals Ltd. Sponsored ADR:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast BiondVax Pharmaceuticals Ltd. Sponsored ADR:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from BiondVax Pharmaceuticals Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	0.45 0.45	- 100%
- Direct Costs	2.10 2.10	400% 400% 467%
Gross Profit	-1.65 -1.65	- -367%
- Selling and Administrative Expenses	0.52 0.52	100% 100% 116%
- Research and Development Expense	4.85 4.85	11% 11% 1,078%
EBITDA	-7.01 -7.01	- -1,558%
- Depreciation and Amortization	1.24 1.24	- 276%
EBIT (Operating Income) EBIT	-8.25 -8.25	28% 28% -1,833%
Net Profit	3.63 3.63	140% 140% 807%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

BiondVax Pharmaceuticals Ltd. Sponsored ADR Stock News

Neutral

PRNewsWire

●

8 days ago

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Scinai files an application for Euro 12 million grant to fund next stage of development Pincell's monoclonal antibody, PC111, is in development for treating Pemphigus, Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) PC111 has already received an Orphan Drug Designation in Pemphigus by the European Medicine's Agency An application will be filed with the FDA for Orphan Drug a...

Neutral

PRNewsWire

●

18 days ago

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

JERUSALEM , March 17, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and in providing CDMO services through its Scinai Bioservices unit, today announced that it will be meeting with investors, showcasing its innovative I&I product pipeline in partnership meetings and exhibiting...

Neutral

PRNewsWire

●

about one month ago

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

JERUSALEM , March 5, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced that it has entered into a Standby Equity Purchase Agreement (the "SEPA") with YA II PN, Ltd.

Company Profile

BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases. It works on M-001, a synthetic peptide-based protein targeting both seasonal and pandemic strains of the influenza virus. The company was founded by Ron Babecoff and Rami Epstein on July 22, 2003 and is headquartered in Jerusalem, Israel.

Head office	Israel
CEO	Amir Reichman
Founded	2003
Website	www.scinai.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now